All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
AAD 2024: Highlights from the IPC report
By Ella Dixon
Bookmark this article
The American Academy of Dermatology (AAD) Annual Meeting 2024 was held in San Diego, U.S., from March 8–12.1 AAD is one of the largest dermatology conferences in the world, with over 1,000 speakers and 300 sessions.1
The International Psoriasis Council (IPC) has provided a report that includes summaries of all 36 talks on psoriasis topics at AAD, and the IPC symposium, which focused on the comprehensive care of psoriasis.1 The IPC is a community of researchers and physicians who work to improve the lives of individuals living with psoriasis.1 Here, we provide a short summary of information included in the report.
Coverage of psoriatic disease1
Key topics covered at AAD included:
-
Biomarkers in psoriasis
-
Evolving treatment landscapes and pipeline therapies
-
Management of nail psoriasis
-
Interleukin inhibitors for psoriasis and psoriatic arthritis
-
Biosimilars
-
Impact of comorbidities in treatment selection
-
Early treatment
-
Psoriasis management in women
Late breaking abstracts1
Topics in the late-breaking abstracts included:
-
52-week results from the phase II KNOCKOUT trial (risankizumab)
-
Light treatment effectiveness (LITE) study
-
Phase II STRIDE study (ESK-001)
-
Phase IIb FRONTIER 2 study (JNJ-77242113)
-
16-week results from a phase III palmoplantar pustulosis trial (apremilast)
-
4-year pooled analysis from BE BRIGHT (bimekizumab)
-
Reducing CD8+ memory T cells in generalized pustular psoriasis (guselkumab)
For a comprehensive understanding of the sessions, the complete report can be found on the IPC website.
- Galimany L. Focus on psoriasis: A report from the 2024 American Academy of Dermatology (AAD) Annual Meeting. International Psoriasis Council. https://psoriasiscouncil.org/congress-reports/2024-aad/?utm_source=Master+List&utm_campaign=d7b57374fe-EMAIL_CAMPAIGN_2019_03_14_06_00_COPY_01&utm_medium=email&utm_term=0_76ed70c5ae-d7b57374fe-106752157. Published April 12, 2024. Accessed April 29, 2024.
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox